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STUDY PROTOCOL Open Access
Protocol for a randomised trial of early
kangaroo mother care compared to
standard care on survival of pre-stabilised
preterm neonates in The Gambia (eKMC)
Helen Brotherton1,2,3* , Abdou Gai2, Cally J. Tann1,4,5, Ahmadou Lamin Samateh6, Anna C. Seale1,
Syed M. A. Zaman7, Simon Cousens1, Anna Roca2 and Joy E. Lawn1
Abstract
Background: Complications of preterm birth cause more than 1 million deaths each year, mostly within the first
day after birth (47%) and before full post-natal stabilisation. Kangaroo mother care (KMC), provided as continuous
skin-to-skin contact for 18 h per day to fully stabilised neonates ≤ 2000 g, reduces mortality by 36–51% at discharge or
term-corrected age compared with incubator care. The mortality effect of starting continuous KMC before stabilisation
is a priority evidence gap, which we aim to investigate in the eKMC trial, with a secondary aim of understanding
mechanisms, particularly for infection prevention.
Methods: We will conduct a single-site, non-blinded, individually randomised, controlled trial comparing two parallel
groups to either early (within 24 h of admission) continuous KMC or standard care on incubator or radiant heater with
KMC when clinically stable at > 24 h of admission. Eligible neonates (n = 392) are hospitalised singletons or twins <
2000 g and 1–24 h old at screening who are mild to moderately unstable as per a trial definition using cardio-
respiratory parameters. Randomisation is stratified by weight category (< 1200 g; ≥ 1200 g) and in random permuted
blocks of varying sizes with allocation of twins to the same arm. Participants are followed up to 28 ± 5 days of age
with regular inpatient assessments plus criteria-led review in the event of clinical deterioration. The primary outcome is
all-cause neonatal mortality by age 28 days. Secondary outcomes include the time to death, cardio-respiratory stability,
hypothermia, exclusive breastfeeding at discharge, weight gain at age 28 days, clinically suspected infection (age 3 to
28 days), intestinal carriage of extended-spectrum beta-lactamase producing (ESBL) Klebsiella pneumoniae (age 28 days),
and duration of the hospital stay. Intention-to-treat analysis will be applied for all outcomes, adjusting for twin
gestation.
Discussion: This is one of the first clinical trials to examine the KMC mortality effect in a pre-stabilised preterm
population. Our findings will contribute to the global evidence base in addition to providing insights into the infection
prevention mechanisms and safety of using this established intervention for the most vulnerable neonatal population.
Trial registration: ClinicalTrials.gov NCT03555981. Submitted 8 May 2018 and registered 14 June 2018. Prospectively
registered.
Keywords: Preterm, Neonate, Kangaroo care, Kangaroo mother care, Skin-to-skin contact, Survival, Infection,
Randomised controlled trial, Pragmatic
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Background
Every year an estimated 14.8 million neonates are born
preterm (< 37 completed weeks of gestation), of which >
80% are in Asia or Sub-Saharan Africa [1], and more
than 1 million die due to complications of prematurity
[2]. An estimated 47% of all prematurity-related deaths
in resource-limited settings occur within the first day
after birth [3] before post-natal stabilisation is complete.
This is the critical period in which to target interven-
tions to improve preterm survival and accelerate pro-
gress toward the Sustainable Development Goal (SDG)
target 3.2 for neonatal mortality reduction. More than
40 countries, many in sub-Saharan Africa, need to more
than double their current progress to meet the target by
2030 [4].
Kangaroo mother care (KMC) is an evidence-based
package recommended as standard care for all clinically
stable (pre-stabilised) neonates < 2000 g [5], which is the
proxy weight used in previous KMC trials as an indica-
tor for preterm birth [6]. Described in Colombia four de-
cades ago, KMC has since been widely adopted as a
cornerstone of neonatal care. The key component is pro-
longed, skin-to-skin contact between neonate and care-
giver, facilitating exclusive breastmilk feeding and
shorter hospital stay [7].
Clinical stability is variably defined in previous KMC
trials with no standardised WHO definition or validated
clinical model for resource-limited settings. In neonates
< 2000 g who have completed stabilisation or post-natal
transition, continuous KMC (aiming for > 18 h/day) re-
duces mortality at discharge or 40 weeks post-menstrual
age by 36–51% [6, 8, 9] compared to incubator care,
with the mortality effect observed only in resource-
limited settings [6]. However, an evidence gap exists for
neonates yet to complete stabilisation, who have greatest
risk of death or adverse outcome [6]. In 20 trials that
assessed mortality at latest follow-up and were included
in three systematic reviews [6, 8, 9], KMC was initiated
at an average age ≤ 4 days in seven trials, with only one
RCT starting continuous KMC in pre-stabilised neonates
within 24 h after birth [10]. This Ethiopian trial reported
a 40% reduction in mortality (RR = 0.57, 95% CI 0.33–
1.00, p < 0.05) but more than half of the unstable neo-
nates were excluded, and the eligibility criteria were un-
clear, leading to high risk of bias [6, 10].
KMC is a safe intervention for unstable neonates in
resource-rich settings with intensive monitoring [11], but
the safety profile in a context of less close clinical moni-
toring is not established [6] and warrants further scrutiny.
KMC works through multiple pathways, many mediated
by skin-to-skin contact [12], including thermal control [6],
neuro-endocrine mechanisms involving oxytocin release
in both mother and neonate [12], reduced cortisol and
stress response [13], cardio-respiratory stabilisation [14],
enhanced breast milk production [6] and empowerment
of the KMC provider in caring for their baby. Alterations
in the neonatal microbiome with intermittent KMC have
also been reported [15] and warrant further exploration to
understand the infection prevention effects of KMC. The
relevance and relative contribution of these mechanisms
for KMC in pre-stabilised neonates are unknown, particu-
larly for infection prevention outcomes, which is an evi-
dence gap for all preterm neonates.
The eKMC trial aims to investigate continuous KMC
in pre-stabilised neonates < 2000 g in a Gambian health
facility setting. A secondary aim is to explore potential
underlying mechanisms of KMC in this high-risk
population.
Objectives
The primary objective of the eKMC trial is to assess the
effect of early continuous KMC on the survival of pre-
stabilised preterm neonates.
Secondary objectives
Secondary objectives include the following:
1. Assess the effect of early continuous KMC on other
important clinical outcomes (growth, late-onset
infections and duration of hospital stay)
2. Evaluate the safety of providing early continuous
KMC to pre-stabilised preterm neonates in a
resource limited facility setting
3. Explore possible mechanisms for hypothesised
beneficial effects of early continuous KMC in pre-
stabilised preterm neonates, focusing on infection
prevention
Methods/design
This article has been prepared according to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) statement (Additional file 1) [16].
Study design
This single-site, pragmatic, non-blinded, individually
randomised superiority trial compares two parallel
groups managed with either continuous KMC started
within 24 h of hospital admission or standard care with
intermittent or continuous KMC when clinically stable
> 24 h after admission. The unit of randomisation is the
mother in a 1:1 ratio with twin participants randomised
to the same arm.
Study setting and context
Recruitment began on 23 May 2018 and is ongoing at
the neonatal unit of Edward Francis Small Teaching
Hospital (EFSTH), the main neonatal referral unit in
The Gambia, with research support from the MRC Unit
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of Gambia at London School of Hygiene & Tropical
Medicine (MRCG at LSHTM).
The Gambia is the smallest country in mainland Af-
rica, with a population of 2.1 million, and it is ranked
174/189 on the Human Development Index (2017) [17].
Neonatal mortality declined from 49 to 26 per 1000 live
births between 1990 and 2018, respectively [18], with
12–14% of Gambian neonates born preterm [1, 19] and
29% of neonatal deaths attributed to complications of
prematurity [3].
A quarter (26%) of the 1400 annual neonatal admis-
sions to EFSTH are due to prematurity [20], and the
neonatal case fatality rate is 38%, with the highest rate
(58%) occurring amongst neonates born < 1500 g [20].
Both in-born (born at the EFSTH maternity unit) and
out-born (born at another health facility or home) neo-
nates are admitted from a mixed rural/urban population.
Neonatal care is typical of secondary level “neonatal
special care” [21] and includes management in incu-
bators or under radiant heaters, respiratory support
via oxygen concentrators or continuous positive air-
way pressure (bubble-CPAP), phototherapy, feeding
support via gastric tubes and intravenous (IV) fluids,
caffeine or aminophylline, phenobarbitone and broad-
spectrum antibiotics. Invasive ventilation, surfactant,
IV fluid pumps and continuous cardio-respiratory
monitoring are unavailable. Continuous KMC was im-
plemented as standard care during the formative trial
phase in September 2017. Intermittent KMC is pro-
vided for a minimum of 60 min at periodic intervals
on the neonatal unit once the neonate is off respira-
tory support and establishing enteral feeds. Neonates
< 2000 g receive continuous KMC on an adjacent
eight-bed KMC unit once they are stable in room air,
are tolerating full enteral feeds and have a willing
caregiver available. Neonates are transferred to the
KMC unit at average 10 days of age (n = 148, SD 7.8)
with the average KMC unit admission lasting for 6.9
days (n = 108, SD 4.0) and 92% (141/151) of dis-
charged neonates attend hospital follow-up at least
once, on average 7.5 days after discharge (n = 141,
range 2–23 days) (unpublished audit data, Sept. 2017
to May 2018, H. Brotherton).
Study population and procedures
Enrolment, interventions and assessments are outlined
in Fig. 1.
The study population is hospitalised neonates < 2000 g
and age 1–24 h old at the start of the screening who
meet the trial definition of mild-moderate instability
based on cardio-respiratory parameters and respiratory
support provision (Fig. 2).
Inclusion criteria are as follows:
 New admission of singleton or twin (inborn or out-
born)
 Weight < 2000 g as per study scale
 Age 1–24 h old when screening begins
 Mother or other caregiver available and willing to
provide intervention
Exclusion criteria are as follows:
 Triplets who are all admitted to the study site
 Congenital malformation not compatible with life or
needing immediate surgical intervention
 Severe jaundice
 Seizures
 Stable as assessed during cardio-respiratory
screening
 Severely unstable as assessed during cardio-
respiratory screening or died during screening
 No study bed available
 Neonates/mothers enrolled in another research
study
 No written informed consent from parent or
caregiver within 24 h of admission.
Screening for eligibility
Eligibility is assessed in all admitted neonates with re-
ferral weight ≤ 2000 g as soon as possible and once >
1 h old. Weight is confirmed using a calibrated
SECA™ 757 digital weighing scale, and source docu-
ments are checked for age and other study involve-
ment. All potentially eligible neonates aged < 24 h
undergo an examination with cardio-respiratory stabil-
ity assessed over 10 min using Nonin™ 2500A pulse
oximeter.
Stable neonates are excluded as it is considered un-
ethical to randomise them to a proven intervention.
Mildly unstable neonates are immediately eligible for
recruitment. Moderately or severely unstable neonates
undergo continuous pulse oximetry with a repeat sta-
bility assessment 3 h later. Severely unstable neonates
are excluded at the repeat 3 h screening, as it is not
possible to provide KMC alongside resuscitation or
CPAP at the study site (Fig. 2). Clinically eligible neo-
nates are recruited if a study bed is available and a
caregiver is willing to both provide the intervention
(if applicable) and give written consent within 24 h of
hospital admission. If eligibility criteria are met but
the caregiver is only available > 3 h after the end of
cardio-respiratory screening, stability is re-checked
prior to consenting to avoid inadvertent recruitment
of stable or severely unstable patients. Standard care
under radiant heater or incubator is provided to all
neonates during the screening period.
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Consent
Sensitisation activities with health workers, pregnant
women and families are conducted at referral health facil-
ities to support recruitment. Written, informed consent
for participation and provision of continuous KMC (in
event of randomisation to intervention arm) is sought
from the first available caregiver at the study site within
24 h of admission by trained study personnel. The parent
is the preferred person to provide informed consent, but
other relatives may provide consent with parental in-
formed consent being sought as soon as possible. Consent
is requested in English with verbal translation into local
languages using a pre-designated dictionary of definitions.
Impartial witnesses are used to support the consenting
Fig. 1 eKMC trial schedule of enrolment, interventions and assessments [16] 1. The start of study procedures (Time 0) is defined as when the
pulse oximeter is attached for baseline continuous cardio-respiratory assessment, immediately prior to the intervention/control procedures
commencing. 2. Participants are reviewed daily until KMC unit admission, after which they are reviewed on days 7, 14, 21, and 28 of age whilst
inpatients and on day 28 as outpatients. Daily reviews are re-started if the baby is transferred back to the neonatal unit. 3. Stability definitions
used during eligibility screening and routine assessments are detailed in Fig. 2. 4. Weight at 5 days of age is taken on calibrated digital scales and
then is taken daily until either discharge or KMC unit admission, after which it is obtained on days 7, 14, 21, and 28 whilst an in-patient and at
the day 28 follow-up if discharged. 5. Skin swab samples are taken from the first person to provide skin-to-skin contact and the mother (if
different) as soon as possible and prior to any skin-to-skin contact. The relationship of the KMC provider to the participant is documented and
correlated with swabs using unique, anonymised identification codes. 6. Outcomes such as feeding method and duration of stay are recorded at
the time of discharge, including for participants hospitalised for > 28 days
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process with caregivers who are unable to read or write
English. Consent for obtaining and future use of paired
maternal recto-vaginal and skin swab samples from the
first KMC provider and mother (if different) is sought be-
fore any skin-to-skin contact occurs.
Randomisation, allocation and blinding
An independent statistician generated a randomisation se-
quence using VBA (Visual Basic Application) within an
Access database to produce two random number tables
with stratification by admission weight categories (< 1200
g or ≥ 1200 g). Random permuted blocks of varying block
sizes were used in a 1:1 allocation. The allocation se-
quence is concealed with sequentially numbered, opaque,
sealed envelopes prepared by an independent researcher
and accessible to study team only. Following the collection
of baseline data, the study nurse opens the next numbered
envelope for the correct weight category. The participant
identifier, date and time are recorded on the outside of
the envelope prior to opening, to identify any subversion
of allocation sequence. Twins are allocated to the same
arm, according to the first eligible twins’ weight.
Given the nature of KMC, blinding parents/caregivers
and study personnel to the allocation arm and the
Fig. 2 eKMC trial definitions of cardio-respiratory instability and eligibility status. 1. Criteria for starting CPAP is a Silverman-Anderson score≥ 4
that does not improve with oxygen therapy and the absence of the following: heart rate < 100 bpm, floppy tone and seizures. 2. The neonate is
recruited if a study bed is available and consent is provided by a willing caregiver
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primary outcome is not possible. Process and secondary
outcome data will be anonymised, and all analyses will
be blinded.
Intervention
The terms KMC and skin-to-skin contact are used as
synonyms in the literature, but the intervention under
study is continuous skin-to-skin contact between neo-
nate and caregiver started within 24 h of admission. The
neonate is naked except for nappy and woollen hat and
is secured with a Thari wrapper (customised KMC wrap-
per developed in South Africa) in a prone, frog-leg pos-
ition on caregivers’ naked chest with head turned
sideways (Fig. 3).
The caregiver sits or lies down whilst the neonate re-
ceives all other treatments (oxygen via nasal prongs,
intravenous (IV) fluids via peripheral venous cannula,
gastric tube feeds and IV medications). If the mother is
unavailable, other relatives (e.g., fathers or grand-
mothers) provide the intervention. KMC is advised for
as long as possible, aiming for ≥ 18 h/day. When not re-
ceiving KMC, the baby remains in an incubator or under
a radiant heater in the same room, with co-habitation of
the radiant heater. If participants meet clinical “stopping
criteria” (Fig. 4c), participants are temporarily withdrawn
from the intervention arm, receive standard incubator
or radiant heater care and re-start KMC once the stabil-
ity criteria are met (Fig. 4d)
Control
The neonate is managed in an incubator or under a radi-
ant heater, naked except for a woollen hat and nappy or
wrapped in a cloth. The parent/caregiver can touch, hold
and feed the neonate as per standard practice but skin-
to-skin contact is not provided until stability criteria are
met (Fig. 4d) and after > 24 h since hospital admission.
Participants then receive intermittent KMC on the neo-
natal unit and continuous KMC on the adjacent KMC
unit (Fig. 4d).
Flow around study site for both arms
After their baseline stability data have been collected, all
participants are transferred to a “trial area” within the
neonatal unit containing four small beds, chairs, incuba-
tors, radiant heater and an oxygen concentrator. This
area can accommodate 8–10 patients with twin partici-
pants sharing incubators. If a neonate subsequently be-
comes severely unstable (Fig. 2), the affected participants
are transferred to the high dependency area and then
follow the standard flow around the neonatal unit. Neo-
nates are moved from “trial area” to the KMC unit once
stability criteria are met (Fig. 2), full enteral feeds have
been tolerated for the previous 12 h, no phototherapy is
required and both a willing caregiver and KMC unit bed
are available. If participants become unwell whilst on the
KMC unit, they are re-admitted to the neonatal unit and
follow the standard patient flow.
Clinical management and study procedures for neonates
in both arms
Baseline anthropometric and clinical data are collected
prior to randomisation with the exception of gestational
age and length (within 48 h of recruitment) and socio-
demographic data (within 28 days). The first available
caregiver is sensitised at baseline for infection control,
provision of KMC, clinical danger signs and when to call
for help. All other routine and emergency treatments,
including discharge, are provided according to a standar-
dised preterm management protocol, based on pre-
existing standard care at the study site and consistent
with WHO guidelines. Compliance with the protocol is
monitored prospectively by trial clinicians. Continuous
monitoring of cardio-respiratory stability with a Nonin™
2500A pulse oximeter occurs for a minimum 24 h of
study participation, until stability is reached (Fig. 2). Dir-
ect nursing observation documents all details of the
KMC provided, including the date and time of first
KMC contact, relationship with the person providing
KMC, KMC session frequency and duration, number of
Fig. 3 An eKMC participant receiving the intervention of ocntinuous
skin-to-skin contact at the same time as other standard care
treatments (H.Brotherton with caregiver consent for publication)
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1 or more of:
Fig. 4 (See legend on next page.)
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neonates receiving KMC from the same provider and
the reason for not providing KMC.
Structured study reviews occur with decreasing inten-
sity as stability improves, with reviews every 6 h for the
first 24 h, daily reviews whilst on the neonatal unit and
weekly reviews during the KMC unit admission (Fig. 4).
The final study review at 28 ± 5 days of age occurs at
EFSTH, with home visits for non-attenders. Caregivers
may withdraw from the study at any time. Data collected
up to the point of the most recent follow-up within 28 ±
5 days of age will be included in the analyses.
Outcome measures
Primary outcome
The primary outcome is all-cause mortality at age 28 days.
Secondary outcomes
Secondary outcomes include the following:
1. Time from start of study procedures to death
The date and time of death is recorded as soon as
possible using the death certificate as a source
document for in-hospital deaths and according to
the caregiver verbal report for out-of-hospital
deaths.
2. Cardio-respiratory stability at 24 h of study
participation (aSCRIP score)
The Stability of Cardio-Respiratory in Preterm
Infants (SCRIP) score is an objective measure of
stability used in previous KMC trials [14, 22]. The
score was modified for relevance to a pre-stabilised
preterm population receiving oxygen (Additional
file 2).
3. Prevalence of hypothermia (axillary temperature <
36.5 oC) at 24 h of study participation
Axillary temperature is measured with an electronic
thermometer as the average of three consecutive
values.
4. Proportion of neonates exclusively
breastfeeding at the time of discharge
Exclusive breast-feeding and use of formula milk
are recorded prospectively by direct observation
and questioning of caregiver at time of discharge.
5. Mean daily weight gain at age 28 ± 5 days (g/day)
This gain is the difference in weight between
baseline and day 28 ± 5 days, as measured on a
calibrated study scale.
6. Incidence of clinically suspected infection from
3 to 28 days of age or latest follow-up
In the absence of a standardised clinical definition
for infection in preterm neonates, a two-step
process is used to identify clinically suspected
infection (Fig. 4a & b). The WHO’s Possible Serious
Bacterial Infection (PSBI) criteria [23] were adapted
to increase the relevance to a hospitalised preterm
population receiving KMC (Fig. 4a). If any aPSBI
criteria are present, a clinician examines the baby
for features of suspected infection [24] (Fig. 4b),
and blood ± cerebro-spinal fluid (CSF) cultures are
obtained if these criteria are met. BACTEC Peds
Plus™/F vials are inoculated with minimum 1ml
venous blood by study clinicians and processed as
soon as possible within 24 h in an automated Bac-
tec® 9050 BD machine at MRCG at LSHTM. Sam-
ples with positive signal undergo sub-culture as per
standard culture methods, species identification by
API 80 system and antibiotic susceptibility testing
by disc diffusion according to CLSI 2017 guidelines.
CSF samples are collected by study clinicians as
soon as possible and in the absence of contra-
indications. CSF is transported to MRCG laborator-
ies at room temperature within 1 h of collection for
routine microbiological and biochemical analysis.
Isolation of clinically significant bacteria are
recorded, with coagulase negative staph (CONS)
and bacillus species predefined as non-pathogenic.
A secondary analysis of the effect of KMC on
confirmed (culture positive) infection is planned.
7. Prevalence of neonatal intestinal carriage of
extended-spectrum beta-lactamase (ESBL)-produ-
cing Klebsiella pneumoniae at age 28 ± 5 days
Rectal swabs are taken with size appropriate
FLOQ™ swabs and stored for batch microbiological
processing. Additional paired maternal and/
or caregiver-neonatal carriage flocked swab samples
obtained at baseline, 7 days (neonatal) and 28 ± 5
days (neonatal) (Fig. 1) are stored for future
microbiological and molecular processing.
8. Mean duration of stay (hours)
Time from study site admission to discharge is
documented prospectively according to source
documents for the first admission episode. This
information indicates if a participant is discharged
after 28 days of age.
Other variables of interest
Adverse events (e.g., abnormal blood glucose, jaundice,
apnoea) are observed in both arms as safety parameters.
(See figure on previous page.)
Fig. 4 Overview of eKMC routine procedures and assessment of clinical deterioration including key trial criteria. 1. New or changed PSBI
definitions to increase relevance for hospitalised preterm neonates. 2. Spontaneous apnoea with no identifiable reason, e.g., not associated with
milk aspiration or end-stage respiratory failure. 3. Re-start criteria also apply to neonates in control arm at the initiation of KMC
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The number, proportion and reason for temporary with-
drawal from the intervention arm is recorded. Weekly
anthropometry (weight, length and head circumference)
provides additional indicators of growth. Continuous
heart rate and oxygen saturation measurements along-
side 6-hourly aSCRIP scores (Additional file 2) are re-
corded for the first 24 h of study participation for a
planned secondary analysis of cardio-respiratory
stability.
Data collection, management and security
All study personnel are trained in ICH-GCP, study ob-
jectives and study-specific procedures, in addition to be-
ing trained in clinical newborn care and KMC. Socio-
demographic, clinical and summary laboratory data are
collected using the REDCap™ data entry system with
built-in range and consistency checks. Length is ob-
tained with a Seca210 measuring mat and head circum-
ference with non-stretchable tape measures using
triplicate measures and regular inter- and intra-observer
standardisation checks with double-blind assessments
against clinician assessment. Vital signs are measured
over 10-min periods to generate mean values, using cali-
brated Nonin™ 2500A pulse oximeters for heart rate and
oxygen saturation with manual recording of respiratory
rate. Gestational age assessment is done by trained clini-
cians using the New Ballard [25] score with regular
inter-observer variability monitoring. All biological sam-
ples are processed or stored (maximum -70 °C) at
MRCG at LSHTM laboratories and biobank (ISO 15189
Accredited), including paired neonatal-caregiver carriage
swab samples and invasive isolates intended for future
exploration of infection mechanisms. Cardio-respiratory
stability data from Nonin™ 2500A pulse oximeters is
downloaded, analysed with NVision™ software and rec-
onciled with the study database. The daily dose of KMC
is automatically calculated before reconciliation with the
study database. All data are securely stored on a MRCG
central server or at the study site with restricted access.
A non-identifiable unique study number for neonate and
caregiver is used to maintain confidentiality for all data,
including stored samples, with linkage of neonatal and
caregiver identifications.
Sample size
A total of 392 subjects (1:1 ratio) is required to detect a
30% relative reduction in the primary outcome (power
80%, alpha = 0.05) with recruitment planned for 2 years.
This number is based on an expected mortality rate of
48% [20], with adjustment for an estimated 15% reduc-
tion in mortality due to trial implementation. Loss to
follow-up rates are expected to be low (< 3%) due to the
restricted geographical area, co-ordination of follow-up
with routine appointments and re-imbursement of travel
expenses.
Statistical analyses
A detailed statistical analysis plan will be made available
at the trial registry before analysis commences. Analysis
of all outcomes will be on an intention-to-treat basis.
Since complete twin allocations account for an estimated
20% of the study population and are independent risk
factors for mortality [26], adjustment for twin correl-
ation will be undertaken using linear mixed effects
models for continuous data and generalised estimating
equations for binary data.
Comparability of participants in two arms
Baseline characteristics will be presented by the alloca-
tion arm using descriptive statistics. Key indicators of
standard hospital care received will be compared for
both arms at baseline and during admission.
Flow of participants
The number and flow of subjects through screening,
randomisation, allocation, follow-up and analysis will be
documented, as per CONSORT 2010 guidelines [27],
with reasons for exclusion, withdrawal and non-analysis
being described (Fig. 5). Participants will be excluded
from the final analysis if they have been permanently
withdrawn.
Primary and secondary outcome analysis
The number of subjects with the primary outcome will
be calculated for each arm and generalised estimating
equations used to calculate risk ratios and the number
needed to treat with confidence intervals. Analysis of
secondary outcomes will be performed according to the
type of data and using either number of subjects or per-
son time as the denominator. Continuous variables will
be compared between arms using random effects
models, and categorical data with generalised estimating
equations. Survival analysis of the time to death within
first 28 days after birth will be performed using cox re-
gression with frailty. In the event of multiple events for
the same participant (e.g., infection), each episode will
be considered an isolated event.
Missing data are expected to be few and will be ad-
dressed with a complete case analysis. Sub-group ana-
lyses for all outcomes will be performed according to
birth weight categories (< 1200 g; ≥ 1200 g) and multiple
birth. Tests for effect modification by weight and mul-
tiple birth will be performed. The following will be cal-
culated for both arms as indicators of adherence: mean
chronological age at first KMC contact, mean time since
admission at first KMC contact, daily dose of KMC
(hours per study day) and average daily dose of in-
Brotherton et al. Trials          (2020) 21:247 Page 9 of 14
patient KMC (per number of days admitted from enrol-
ment). A sensitivity analysis of all outcomes will be per-
formed according to average in-patient daily dose of
KMC.
Safety reporting and study monitoring against ICH-GCP
standards
Adverse events are any clinical event resulting in a change
in management of the participant after enrolment and
until age 28 days. Serious adverse events (SAE) are defined
as death, life-threatening events (e.g., apnoea requiring
bag-valve-mask ventilation, or severe instability), events
carrying a risk of permanent or temporary disability (e.g.,
suspected meningitis), re-hospitalisation within 28 days of
age and prolonged hospitalisation for ≥ 28 days.
A local safety monitor, the sponsor and the trial moni-
tors are informed of all SAEs within 24 h of the study
team being aware with a detailed report sent within 2
working days for fatal and 5 days for a non-fatal SAE. All
fatal SAEs are reported to the ethics committees
monthly and within 7 days if related to the intervention.
Non-fatal SAE’s are communicated to the ethics com-
mittees annually or within 14 days if related to the inter-
vention. A Data Safety Monitoring Board (DSMB)
receives a bi-monthly safety report with bi-annual meet-
ings to monitor recruitment, progress and safety. DSMB
members include the clinical trialist/statistician (chair), a
neonatologist experienced in a similar setting, a West
African clinical trialist and an independent statistician.
An un-blinded interim analysis will be conducted after
randomisation of 50% of target sample size with pre-
specified stopping rules for efficacy, using the Haybittle-
Peto rule [28, 29] and will inform recommendations to
the Trial Steering Committee (TSC), who will make the
Fig. 5 Trial flow diagram, as per CONSORT guidelines 2010 [27]
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final decision on study continuation. Study procedures
and documents are monitored for compliance to ICH-
GCP standards by MRCG monitors every 3–6 months,
with auditing determined by the sponsor.
Discussion
Evaluating the effect of continuous KMC before full
stabilisation is a global research priority, stated by
WHO [6] with the potential to contribute towards re-
ducing the unacceptably high global neonatal mortal-
ity, enabling progress towards the neonatal mortality
target SDG3.2 by 2030, as well as promoting a
family-centred approach to newborn care. eKMC is
one of the first trials to address this evidence gap and
is expected to provide robust evidence in addition to
novel mechanistic insights, particularly regarding in-
fections, which are one of the major pathways to
mortality for preterm neonates.
KMC reduces severe infections (6.6% vs 13.1%, RR =
0.5, 95% CI 0.36–0.69) and nosocomial infections (4% vs
11%, RR = 0.35, 95% CI 0.22–0.54) with intermittent or
continuous KMC in stable neonates [6]. However, previ-
ous KMC trials have lacked clear case definitions for in-
fection and a paucity of microbiologically confirmed
data are available from resource-limited settings [6].
eKMC will contribute towards understanding the infec-
tion prevention effects of KMC by using a validated
nosocomial risk score [24] microbiological testing and
exploration of impact on carriage of antimicrobial resist-
ant bacteria.
During eKMC trial piloting, we identified important
challenges, which are outlined below with mitigating
approaches:
Challenge 1 - Recruitment: The unavailability of
caregivers willing to consent and provide the
intervention within 24 h after birth is a major
recruitment barrier due to high rates of maternal illness
or post-caesarean section and absence of other family
members at the hospital during the early admission
period. Sensitisation activities with pregnant women
and their families and health workers are undertaken at
referral centres to encourage recruitment. A high
proportion of either severe instability or death occurs
before or during the screening process, reflecting the
high proportion of out-born neonates and a vulnerable
population. Access to sufficient study beds for the
intervention was a limiting factor, and the number of
study beds was increased from 2 to 4 during the
piloting period to facilitate recruitment.
Challenge 2 - Non-blinded trial: KMC could not be
blinded for the family or researchers. Selection and
allocation bias are prevented through rigorous
screening and randomisation procedures with objective
stability markers, and transparent reporting of non-
recruitment will be performed. Treatment bias is
minimised via a protocolised approach to standard care
with prospective monitoring of adherence, comparable
clinical monitoring and caregiver education for both arms.
Challenge 3 - Twins: Like much of West Africa, the
twin birth rate in The Gambia is high at 16.7/1000 live-
births [30] with greater risk of premature delivery and
neonatal death compared to singletons [26, 30].
Evaluation of the intervention in twins is essential for
generalisability of results and to target the most
vulnerable neonates. Investigators anticipate that 30%
of participants will be twin gestation, with complete
twin enrolment accounting for 20% of the study
population. This may lead to differences in provision of
the intervention in addition to independently impacting
the trial outcomes. All efforts to adjust for multiple
births will be made during analysis.
Challenge 4 – Improvements to standard care leading
to potential dilution of the intervention effect and risk
of inadequate power: Alongside externally driven
improvements to newborn care at the study site, eKMC
implementation has resulted in major improvements to
standard care for both trial and non-trial neonates. In
collaboration with the hospital, the Gambian Govern-
ment Ministry of Health and Social Welfare and UNICEF
The Gambia, an eight-bed KMC unit was established,
and continuous KMC was embedded in standard care in
2017. A protocolised approach to standard care of pre-
term neonates was also introduced at the site to reduce
the risk of treatment bias. Although highly beneficial
from an individual patient perspective, these improve-
ments in care are expected to reduce both the power of
detecting a difference in the primary outcome and may
reduce differences between allocation arms, diluting the
intervention effect. These changes to standard care will
be explored in a linked process evaluation, based on the
MRC guidance for evaluation of complex interventions
[31] and using data collected before and after trial imple-
mentation. Activities will include a survival analysis of
neonatal case fatality rates using published data from the
study site [20] and prospective data collection for all ad-
missions over the trial period, tracking of the changes
made to standard newborn care, and KMC implementa-
tion progress monitoring [32].
If early KMC for pre-stabilised neonates is shown to be
beneficial, we need to understand how to implement in a
real-world setting. eKMC-generated implementation and
safety data will be valuable, particularly when combined
with similar trials, such as the multi-site OMWaNA trial
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in Uganda [33] and WHO-led multi-centre I-KMC trial
[34]. We aim to align data definitions and maximise op-
portunities for pooled analyses with the OMWaNA trial.
The primary outcome results of the eKMC trial will
contribute to the global evidence base for use of KMC
before stabilisation in preterm neonates, with secondary
outcome results and other analyses providing insights to
how KMC is effective, particularly regarding infection
prevention. The eKMC trial aims to inform one of the
great divides between resource-limited and resource-rich
settings and improve the chance for newborns every-
where to survive and thrive.
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